- Home
- HOTH vs AIM Comparison
HOTH vs AIM Comparison
Compare HOTH & AIM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HOTH
- AIM
- Stock Information
- Founded
- HOTH 2017
- AIM 1966
- Country
- HOTH United States
- AIM United States
- Employees
- HOTH N/A
- AIM N/A
- Industry
- HOTH Biotechnology: Pharmaceutical Preparations
- AIM Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- HOTH Health Care
- AIM Health Care
- Exchange
- HOTH Nasdaq
- AIM Nasdaq
- Market Cap
- HOTH 8.3M
- AIM 9.8M
- IPO Year
- HOTH 2019
- AIM N/A
- Fundamental
- Price
- HOTH $1.06
- AIM $0.14
- Analyst Decision
- HOTH Strong Buy
- AIM Strong Buy
- Analyst Count
- HOTH 4
- AIM 2
- Target Price
- HOTH $4.75
- AIM $2.75
- AVG Volume (30 Days)
- HOTH 673.3K
- AIM 1.5M
- Earning Date
- HOTH 03-27-2025
- AIM 04-01-2025
- Dividend Yield
- HOTH N/A
- AIM N/A
- EPS Growth
- HOTH N/A
- AIM N/A
- EPS
- HOTH N/A
- AIM N/A
- Revenue
- HOTH N/A
- AIM $190,000.00
- Revenue This Year
- HOTH N/A
- AIM N/A
- Revenue Next Year
- HOTH N/A
- AIM $1,693.10
- P/E Ratio
- HOTH N/A
- AIM N/A
- Revenue Growth
- HOTH N/A
- AIM N/A
- 52 Week Low
- HOTH $0.58
- AIM $0.12
- 52 Week High
- HOTH $3.80
- AIM $0.62
- Technical
- Relative Strength Index (RSI)
- HOTH 42.86
- AIM 36.62
- Support Level
- HOTH $1.01
- AIM $0.12
- Resistance Level
- HOTH $1.09
- AIM $0.21
- Average True Range (ATR)
- HOTH 0.08
- AIM 0.02
- MACD
- HOTH -0.02
- AIM -0.00
- Stochastic Oscillator
- HOTH 25.93
- AIM 22.88
About HOTH Hoth Therapeutics Inc.
Hoth Therapeutics Inc is a development-stage biopharmaceutical company. It is focused on targeted therapeutics for patients suffering from conditions such as atopic dermatitis, also known as eczema, chronic wounds, psoriasis, asthma, and acne. The company owns the BioLexa Platform which combines an FDA-approved zinc chelator with one or more approved antibiotics in a topical dosage form to address unchecked eczema flare-ups.
About AIM AIM ImmunoTech Inc.
AIM ImmunoTech Inc is an immuno-pharma company focused on research and development of therapeutics to treat immune disorders and viral and cancer diseases. AIM's flagship products include Ampligen (Rintatolimod), a drug of large macromolecular RNA molecules for cancer and viral diseases, and the drug Alferon N Injection for a category of STD infection. Clinical trials of Ampligen include studies of cancer patients with renal cell carcinoma, malignant melanoma, colorectal cancer, advanced recurrent ovarian cancer, and triple-negative metastatic breast cancer. It is also advancing Ampligen as a potential treatment for COVID-19. FDA has authorized the first human trial assessing the safety and effectiveness of Ampligen in combination with interferon alfa-2b, in cancer patients with COVID-19.